Medicus Pharma wins central IRB approval for optimized Phase 2 Teverelix AUR study
MDCX•Central IRB clears optimized Phase 2 study
Medicus Pharma received written FDA feedback supporting its optimized Phase 2 Teverelix study in acute urinary retention.
Advarra, the central IRB, cleared the ANT-2111-02 protocol with modifications through June 18, 2027.
The redesigned trial targets about 126 patients versus roughly 390 previously planned, aiming to speed dose and route selection.
